Lung Cancer: updates in lung cancer biomarkers and targeted therapies-FSP Precision Medicine Speaker #1 - Lung Cancer

FSP Precision Medicine Speaker #1 - Lung Cancer - Bruna Pellini

Video Transcription

Video Summary

The speaker gave a selective overview of lung cancer oncogene drivers, focusing on rarer alterations rather than KRAS or EGFR. He reviewed recent advances in targeted therapy for ROS1, BRAF, MET exon 14 skipping, RET, HER2, NTRK, and NRG fusions. For ROS1, newer agents like repotrectinib and taletrectinib offer strong responses and better CNS control, though some cause neurologic side effects. In BRAF V600E disease, combination targeted therapy is effective, but toxicity is a major issue; selected patients may also do well with chemo-immunotherapy. MET exon 14 therapies can be hard to tolerate because of prominent edema. RET inhibitors, especially selpercatinib, show excellent efficacy and even adjuvant use. HER2, NTRK, and NRG-targeted treatments were also discussed, with emphasis on efficacy, toxicity, and the importance of molecular testing to guide drug selection.

Keywords

lung cancer oncogene drivers

targeted therapy

ROS1

BRAF V600E

MET exon 14 skipping

molecular testing